Transforming growth factor-betas (TGF-betas) are potent inhibitors of epithelial cell growth. Recently the type II TGF-beta receptor has been shown to be diminished or absent in a number of human malignancies, implicating loss of TGF-beta function as one mechanism contributing to tumor development. We have tested the importance of the TGF-beta system in epithelial homeostasis in vivo by generating transgenic animals locally overexpressing a dominant negative mutant form of the type II TGF-beta receptor (DNR) in order to knock out response to TGF-beta in select epithelia. High level expression of the DNR construct in the exocrine pancreas results in progressive atrophy of the acinar compartment, associated with ductal metaplasia and fatty replacement. Enhanced proliferation of acinar cells is observed, consistent with a key role for endogenous TGF-betas in limiting proliferation and maintaining structural integrity of the exocrine pancreas. Overexpression of the DNR in the mammary glands results in increased lobulo-alveolar side-branching and, importantly, in an enhanced susceptibility to tumorigenesis induced by the carcinogen dimethylbenzanthracene. Similarly, introduction of the DNR into a premalignant rat prostate cell line causes the cells to become tumorigenic in nude mice. These studies provide the first in vivo demonstration of the tumor suppressor function of the TGF-beta receptor. We have also shown that loss of just one TGF-beta1 allele is sufficient to cause increases in cell turnover rates and enhanced susceptibility to tumorigenesis in the liver and lung of genetically modified mice. Since the resulting tumors retain the remaining wildtype TGF-beta1 allele, this distinguishes TGF-beta1 from classical tumor suppressor genes. We are currently analyzing the underlying molecular mechanisms. Results from all these experiments should give clinically useful insights into the physiological functions of TGF-betas during tumor initiation, promotion and progression, and illuminate how the system could be most effectively used in novel chemopreventive strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC005785-04
Application #
6100874
Study Section
Special Emphasis Panel (LC)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kohn, Ethan A; Yang, Yu-an; Du, Zhijun et al. (2012) Biological responses to TGF-? in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. Mol Cancer Res 10:1389-99
Kohn, Ethan A; Du, Zhijun; Sato, Misako et al. (2010) A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGF? signaling in the mammary gland. Breast Cancer Res 12:R83
Kim, Ran-Ju; Kim, Soo-Rim; Roh, Kyung-Jin et al. (2009) Ras activation contributes to the maintenance and expansion of Sca-1(pos) cells in a mouse model of breast cancer. Cancer Lett :
Laverty, H G; Wakefield, L M; Occleston, N L et al. (2009) TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev 20:305-17
Nam, Jeong-Seok; Terabe, Masaki; Mamura, Mizuko et al. (2008) An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68:3835-43
Nam, Jeong-Seok; Terabe, Masaki; Kang, Mi-Jin et al. (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68:3915-23
Tang, Binwu; Yoo, Naomi; Vu, Mary et al. (2007) Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 67:8643-52
Nam, Jeong-Seok; Hirohashi, Setsuo; Wakefield, Lalage M (2007) Dysadherin: a new player in cancer progression. Cancer Lett 255:161-9
Nam, Jeong-Seok; Suchar, Adam M; Kang, Mi-Jin et al. (2006) Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66:6327-35
Nam, Jeong-Seok; Kang, Mi-Jin; Suchar, Adam M et al. (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66:7176-84

Showing the most recent 10 out of 16 publications